BioNTech (BNTX)
(Delayed Data from NSDQ)
$87.21 USD
+0.50 (0.58%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $87.20 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Balance Sheet
Fiscal Year End for BioNTech SE Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 17,911 | 14,818 | 2,454 | 1,539 | 583 |
Receivables | 2,527 | 7,529 | 14,649 | 190 | 14 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 387 | 463 | 595 | 73 | 13 |
Other Current Assets | 309 | 286 | 134 | 102 | 17 |
Total Current Assets | 21,134 | 23,097 | 17,832 | 1,904 | 627 |
Net Property & Equipment | 820 | 642 | 382 | 259 | 104 |
Investments & Advances | 1,273 | 85 | 25 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 88 | 242 | 16 | 184 | 0 |
Intangibles | 1,263 | 231 | 239 | 187 | 100 |
Deposits & Other Assets | 90 | 7 | 1 | 1 | 0 |
Total Assets | 24,900 | 24,527 | 18,729 | 2,649 | 893 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 383 | 215 | 189 | 117 | 23 |
Current Portion Long-Term Debt | 30 | 38 | 154 | 10 | 2 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 569 | 628 | 1,856 | 0 | 0 |
Other Current Liabilities | 1,259 | 2,228 | 1,920 | 565 | 130 |
Total Current Liabilities | 2,241 | 3,109 | 4,119 | 692 | 155 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 43 | 7 | 79 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 207 | 186 | 203 | 264 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 497 | 95 | 257 | 125 | 186 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2,988 | 3,396 | 4,658 | 1,082 | 341 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 269 | 262 | 291 | 281 | 260 |
Capital Surplus | 1,331 | 1,926 | 1,981 | 1,262 | 293 |
Retained Earnings | 21,390 | 19,842 | 11,692 | 0 | 0 |
Other Equity | -1,066 | -894 | 111 | 29 | 5 |
Treasury Stock | 12 | 6 | 5 | 5 | 6 |
Total Shareholder's Equity | 21,912 | 21,131 | 14,071 | 1,567 | 553 |
Total Liabilities & Shareholder's Equity | 24,900 | 24,527 | 18,729 | 2,649 | 893 |
Total Common Equity | 21,912 | 21,131 | 14,071 | 1,567 | 553 |
Shares Outstanding | 237.70 | 242.60 | 242.50 | 226.20 | 226.20 |
Book Value Per Share | 92.18 | 87.10 | 58.03 | 6.93 | 2.44 |
Fiscal Year End for BioNTech SE Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 17,911 | 17,141 | 16,964 | 13,420 |
Receivables | NA | 2,527 | 2,494 | 3,260 | 7,496 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 387 | 452 | 489 | 455 |
Other Current Assets | NA | 309 | 319 | 238 | 190 |
Total Current Assets | NA | 21,134 | 20,407 | 20,951 | 21,560 |
Net Property & Equipment | NA | 820 | 793 | 754 | 686 |
Investments & Advances | NA | 1,273 | 1,407 | 1,499 | 555 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 88 | 227 | 261 | 264 |
Intangibles | NA | 1,263 | 1,122 | 547 | 406 |
Deposits & Other Assets | NA | 90 | 0 | 3 | 5 |
Total Assets | NA | 24,900 | 24,170 | 24,235 | 23,700 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 383 | 242 | 249 | 32 |
Current Portion Long-Term Debt | NA | 30 | 44 | 42 | 40 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 569 | 593 | 605 | 565 |
Other Current Liabilities | NA | 1,259 | 1,088 | 1,087 | 1,028 |
Total Current Liabilities | NA | 2,241 | 1,967 | 1,983 | 1,665 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 43 | 47 | 5 | 6 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 207 | 176 | 182 | 185 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 357 | 358 | 91 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 2,988 | 2,547 | 2,529 | 1,947 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 269 | 271 | 271 | 267 |
Capital Surplus | NA | 1,331 | 1,337 | 1,553 | 1,662 |
Retained Earnings | NA | 21,390 | 21,012 | 20,875 | 20,754 |
Other Equity | NA | -1,066 | -985 | -984 | -922 |
Treasury Stock | NA | 12 | 12 | 10 | 8 |
Total Shareholder's Equity | NA | 21,912 | 21,623 | 21,706 | 21,753 |
Total Liabilities & Shareholder's Equity | NA | 24,900 | 24,170 | 24,235 | 23,700 |
Total Common Equity | 0 | 21,912 | 21,623 | 21,706 | 21,753 |
Shares Outstanding | 237.70 | 237.70 | 239.70 | 240.90 | 243.20 |
Book Value Per Share | 0.00 | 92.18 | 90.21 | 90.10 | 89.44 |